Brian Los
Family Medicine · Titusville, PANPI 1497747588
Payments from drug & device makers
Across 976 payments — averaging $14.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$2K
- Novo Nordisk$2K
- Boehringer Ingelheim$1K
- AstraZeneca$1K
- Merck$917
- AbbVie$900
- plus $7K from 42 others
What the payments were for
- Food & beverage$14,223100%
- Education$440%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$14,267 in reported general payments places this provider in the 95th percentile of 4,967 family medicine providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 241 | $238,071 |
| JardianceEmpagliflozin | 107 | $136,516 |
| XareltoRivaroxaban | 98 | $105,492 |
| OzempicSemaglutide | 64 | $76,838 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 88 | $70,234 |
| EntrestoSacubitril/Valsartan | 50 | $50,330 |
| FarxigaDapagliflozin Propanediol | 32 | $40,539 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 71 | $36,782 |
| Invega SustennaPaliperidone Palmitate | 11 | $34,861 |
| Breo ElliptaFluticasone/Vilanterol | 59 | $32,729 |
| MyrbetriqMirabegron | 40 | $32,401 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 25 | $32,121 |
| TrulicityDulaglutide | 21 | $23,707 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 21 | $17,662 |
| JanuviaSitagliptin Phosphate | 29 | $14,166 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $1,521 | $238,071241 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta | $890 | $142,698229 claims |
| Johnson & JohnsonXarelto, Invega Sustenna | $266 | $140,353109 claims |
| Boehringer IngelheimJardiance | $1,381 | $136,516107 claims |
| Novo NordiskOzempic | $1,502 | $76,83864 claims |
| NovartisEntresto | $438 | $50,33050 claims |
| AstraZenecaFarxiga | $1,260 | $40,53932 claims |
| Astellas Pharma US IncMyrbetriq | $889 | $32,40140 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $408 | $32,12125 claims |
| Lilly USA, LLCTrulicity | $835 | $23,70721 claims |
| MerckJanuvia | $917 | $14,16629 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,967 family medicine providers in Pennsylvania.
Other family medicine in Titusville
- Kem YenalPhila$12.6M
- Marcy FleckerSmithfield$6.9M
- Tiffany PlutoScottdale$4.8M
- Bryce PalchickPittsburgh$4.7M
- Harris CohenHorsham$3.7M
- Shari RozenPittsburgh$2.9M
- Richard CookUniontown$2.1M
- Bruce GebhardtErie$2.1M
- Peter CognettiScranton$1.9M
- Bradley FoxErie$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.